Ai Wakasugi

Publications (2)4.62 Total impact

• Article: Organic nanotubes for drug loading and cellular delivery.

  Ai Wakasugi, Masumi Asakawa, Masaki Kogiso, Toshimi Shimizu, Mamiko Sato, Yoshie Maitani
  [show abstract] [hide abstract]
  ABSTRACT: Organic nanotubes made of synthetic amphiphilic molecules are novel materials that form by self-assembly. In this study, organic nanotubes with a carboxyl group (ONTs) at the surface were used as a carrier for the anticancer drug doxorubicin, which has a weak amine group. The IC(50) values of ONT for cells were higher than that of conventional liposomes, suggesting that ONTs are safe. The results showed that the drug loading of ONTs was susceptible to the effect of ionic strength and H(+) concentration in the medium, and drug release from ONTs was promoted at lower pH, which is favorable for the release of drugs in the endosome after cellular uptake. ONTs loaded with the drug were internalized, and the drug was released quickly in the cells, as demonstrated on transmission electron microscopy images of ONTs and the detection of a 0.05% dose of ONT chelating gadolinium in the cells. Moreover, ONT could be modified chemically with folate by simply mixing with a folate-conjugate lipid. Therefore, these novel, biodegradable organic nanotubes have the potential to be used as drug carriers for controlled and targeting drug delivery.
  International journal of pharmaceutics 07/2011; 413(1-2):271-8. · 2.96 Impact Factor
• Article: Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature.

  Atsuko Hioki, Ai Wakasugi, Kumi Kawano, Yoshiyuki Hattori, Yoshie Maitani
  [show abstract] [hide abstract]
  ABSTRACT: In this study, to establish the conditions of a drug release assay for PEGylated liposome formulations that relates with the drug stability profile in serum in vivo, the influences of incubation temperature and serum protein in the release buffer were examined using liposomal doxorubicin (DXR). In in vitro drug release assays, a PEGylated liposomal DXR in phosphate buffered saline (PBS) at 37 degrees C showed higher drug release rate than non-PEGylated formulation although PEGylated liposomal DXR had higher stability than an equivalent non-PEGylated formulation following intravenous injection. When bovine serum albumin (BSA) and increased temperature, 50 degrees C, were used to accelerate drug release from the liposomes and to mimic in vivo result, non-PEGylated liposomal DXR showed conversely higher release than a PEGylated formulation. Since high temperature increased BSA adsorption onto liposomes, BSA may cause non-PEGylated liposomes instability more than PEGylated ones, resulting in the reverse of the drug release rate of both liposomes. This finding suggested that the conditions in the drug release assay with PEGylated liposomal DXR may be able to be set by a combination of BSA and providing additional thermal energy.
  Biological & Pharmaceutical Bulletin 01/2010; 33(9):1466-70. · 1.66 Impact Factor